XML 32 R21.htm IDEA: XBRL DOCUMENT
v3.19.1

Earnings Per Share | 3 Months Ended
--- | ---
Mar. 31, 2019
Earnings Per Share [Abstract] |
Earnings Per Share | Earnings Per Share The calculations of earnings per share are as follows:
| Three Months Ended March 31,
($ and shares in millions except per share amounts) | 2019 |  | 2018
Net income attributable to Merck & Co., Inc. | $ | 2,915 |  |  | $ | 736 |
Average common shares outstanding | 2,585 |  |  | 2,695 |
Common shares issuable (1) | 18 |  |  | 15 |
Average common shares outstanding assuming dilution | 2,603 |  |  | 2,710 |
Basic earnings per common share attributable to Merck & Co., Inc. common shareholders | $ | 1.13 |  |  | $ | 0.27 |
Earnings per common share assuming dilution attributable to Merck & Co., Inc. common shareholders | $ | 1.12 |  |  | $ | 0.27 |
(1) | Issuable primarily under share-based compensation plans.
For the three months ended March 31, 2019 and 2018, 2 million and 14 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -URI http://asc.fasb.org/topic&trid=2144383 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration